The exploration and adoption of best practices in health by public institutions and non-governmental organizations as well has been growing in recent years. ASSET experts recognize the importance of these activities. Thus, they will gather examples from all around Europe and present them on a dedicated page.
But what exactly are “best practices”, and what are the differences between best and good practices?
In 2009 A(H1N1) pandemic, vaccines were ready and could be supplied only when the peak of the pandemic was already decreasing in most European countries, discouraging people from getting vaccinated. Since the disease was not as severe as it was feared in the beginning, the consequences of this delay were not that serious, even if some lives could have been saved if the vaccines were available in advance. Ebola vaccine also arrived to West Africa when the epidemic was over, while a zika vaccine is still very far away. According to Thomas Breuer, however, GSK Chief Medical Officer, in case of another flu pandemic, a better cooperation among stakeholders and new technologies could accelerate the production and supply of new vaccines.
One day, eight countries, fifty participants for each of them, open discussions and a series of questions. These are the ingredients of the citizen consultations organized by ASSET on September 24th, to voice people’s opinion on epidemic preparedness and response.
Vaccines have had broad medical impact, but existing vaccine technologies and production methods are limited in their ability to respond to certain pathogens. Other hurdles are due to difficulties in large scale production. MycoSynVac project proposes a new way for developing vaccines, by using of cutting-edge synthetic biology methodologies to engineer Mycoplasma pneumoniae as a universal chassis for vaccination.
Parents, healthcare workers, bloggers and science communicators have launched a positive experience in Italy, with the aim of sharing and promoting scientific information towards an important public health goal: to face the drop in vaccine coverage.
Citizens from the eight Countries partner of the ASSET project will gather on September 24th to discuss and express themselves through a public consultation on some of the key topics of the project:
There are times when science seems to be losing its connection to society and its needs, and its objectives are not fully understood, even if they are well intended. The lack of a common language on one hand and the rapid progress in many areas of research on another have increased the public's concern. It is also contributing to the ambivalence surrounding the role that science and technology are playing in everyday life. However, science and scientists cannot and should not work in isolation, and advances in science and technology are not an objective in their own right.
Public engagement that sets citizens and stakeholders as co-designers and collaborators of R&I activities can contribute to more dynamic and responsible governance of research and innovation. Public Engagement for Research, Practice and Policy conference, to be organized on November 16-17 in Brussels, calls for experts, stakeholders, policy-makers, entrepreneurs, researchers, regional authorities and Commission officials to a joint discussion on this theme.
One of the main source of distrust towards public health authorities is the suspect of hidden connections with the pharmaceutical industry, but, in case of a severe pandemic, an adequate supply of antivirals and vaccines is essential. ASSET asked Norman Begg, GSK Vice President, Head of Scientific Affairs and Public Health, Vaccines, what kind of agreements exist for Public Health Emergencies of International Concern (PHEIC) or of a pandemic, between big pharma and WHO. The answer for the two situations is not the same.
